British pharmaceutical company Bioglan - which is quoted on the Irish Stock Exchange - has acquired the rights to a range of pain killing drugs from Sweden's Pharmacia for £2 million sterling.
Bioglan is buying five immediate-release morphine products in Sweden together with licensing rights to market the drugs internationally.
The portfolio comprises a range of injectables and tablets, principally supplied to hospitals in Sweden, with aggregate annual sales of some £1 million.